Autopsy report · NCT04770467
A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19
Cause of deathStaffing, sites or logistics
“The study will no longer move forward due to recent changes in COVID-19 cases in Hong Kong.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Brii Biosciences, Inc.
- Sponsor type
- Industry
- Conditions
- COVID-19
- Interventions
- BRII-196 and BRII-198; Placebo
- Participants
- 0
- Sites
- 1
- Countries
- China
Trials that died the same way
- T-MACS Decision Aid: a Randomized, Controlled Point of Care Trial
“CI no longer wishes to complete this study due to Covid-19” - Effects of Community-center Based Dietary Intervention on Frailty Prevention and Regression in the Elderly.
“Due to the impacts of COVID-19, the study had to terminate.” - A Multi-Component Nutrition Program for Pregnant and Parenting Teens
“The study never launched due to several COVID-19 related barriers.” - A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
“Termination due to challenges related to the operational feasibility of the study, taking into account the current epidemiology and declining hospitalization rates for severe COVID-19.” - The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
“Study ended early due to COVID-19”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.